Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Abstract Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach t...
Saved in:
Similar Items
-
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program
by: Michael P. Harms, et al.
Published: (2025-04-01) -
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
by: Kelly Allott, et al.
Published: (2025-03-01) -
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
by: Jean Addington, et al.
Published: (2025-04-01) -
Modelling the impact of environmental and social determinants on mental health using generative agents
by: Joseph Kambeitz, et al.
Published: (2025-01-01) -
Computational modelling reveals neurobiological contributions to static and dynamic functional connectivity patterns
by: Linnea Hoheisel, et al.
Published: (2025-07-01)